Replies to post #12790 on The Rising Influence of Rising Affluence

[DewDiligence]

MDLZ offered $23B, but HSY said no:

http://finance.yahoo.com/news/abbvies-humira-adalimumab-receives-u-002600396.html

No company accepts the first unsolicited offer.

Unusual wrinkle: A charitable trust has voting control of HSY.